

Investing 4 Life
7.8K posts

@StockBullPicks
Not Financial Advice - postings are never a recommendation to buy - perform your own due diligence before putting any money at risk. *NOT A FINANCIAL ADVISOR*







$MAJI in October the company was awareded Orphan Drug Designation for its exosome-based GBM treatment also known as Glioblastoma multiforme. Only 11% of orphan drug designations are awarded at the preclinical stage. "Our breakthrough exosomal technology has the ability to deliver a wide range of therapeutics, including genetic material, into cells afflicted with cancer, such as GBM. The therapeutic technology presented in this orphan drug application is a method for using exosomes loaded with desired nucleic acids, in the effective treatment of GBM when combined with currently available standard anticancer therapy." They plan to work with investment bankers to expand and monetize the therapy. A product like this could bring in 10's of millions of dollars alone to the company. otcmarkets.com/stock/MAJI/new…






$MAJI currently owns a controlling stake in $LMMY which is a SEC-reporting stock trading at $0.49 per share - 10X MAJI current PPS. With the strategic alignment of the two entities, MAJI owns 51% of their restricted stock making them the controlling shareholder. Per their November 2025 PR this will be used to raise capital and ensure the funding is non-dilutive to MAJI shareholders. LMMY intends to begin the process to uplist to Nasdaq. otcmarkets.com/stock/MAJI/new…


Exciting news for $MAJI: When our site is live! Anyone interested in joining our groundbreaking cancer screening study can now sign up directly online. Once enrolled, you’ll receive a comprehensive at-home collection kit with clear instructions for a seamless return. Your results will be delivered securely via email, and all data is strictly managed under HIPAA guidelines to ensure your privacy. Join us in advancing early detection!..more to come.


Hey OTC Community! There will be a NO HOLDS BARRED Spaces TODAY at 4 pm est. 👉Come share your thoughts, favorite set-ups & latest due diligence. The floor will be YOURS! $AAGC $AURI $CVAT $CYBL $ECGI $GGSM $HIRU $MAJI $PHSE $SFWJ $TRWD $VXIT x.com/i/spaces/1lKQR…

Exciting news for $MAJI: When our site is live! Anyone interested in joining our groundbreaking cancer screening study can now sign up directly online. Once enrolled, you’ll receive a comprehensive at-home collection kit with clear instructions for a seamless return. Your results will be delivered securely via email, and all data is strictly managed under HIPAA guidelines to ensure your privacy. Join us in advancing early detection!..more to come.




$MAJI currently owns a controlling stake in $LMMY which is a SEC-reporting stock trading at $0.49 per share - 10X MAJI current PPS. With the strategic alignment of the two entities, MAJI owns 51% of their restricted stock making them the controlling shareholder. Per their November 2025 PR this will be used to raise capital and ensure the funding is non-dilutive to MAJI shareholders. LMMY intends to begin the process to uplist to Nasdaq. otcmarkets.com/stock/MAJI/new…

$MAJI — the telehealth company with which we are finalizing a definitive agreement — is currently renegotiating terms with 1,900 clinics to expand its role as sole distributor beyond testosterone. The existing testosterone program alone generates approximately $4 per script across an estimated 2,000 daily prescriptions, highlighting meaningful revenue potential with significant upside as the partnership broadens. #OTC


$MAJI with the numbers below on the testosterone program and say it's only 260 days a year without the weekend at 1,900 patients @ $4 per day this equates to almost $2M alone a year assuming there aren't any other programs in the works. 🧐 365 days per year is $2.8M roughly. ✍️

$MAJI currently owns a controlling stake in $LMMY which is a SEC-reporting stock trading at $0.49 per share - 10X MAJI current PPS. With the strategic alignment of the two entities, MAJI owns 51% of their restricted stock making them the controlling shareholder. Per their November 2025 PR this will be used to raise capital and ensure the funding is non-dilutive to MAJI shareholders. LMMY intends to begin the process to uplist to Nasdaq. otcmarkets.com/stock/MAJI/new…

$MAJI — the telehealth company with which we are finalizing a definitive agreement — is currently renegotiating terms with 1,900 clinics to expand its role as sole distributor beyond testosterone. The existing testosterone program alone generates approximately $4 per script across an estimated 2,000 daily prescriptions, highlighting meaningful revenue potential with significant upside as the partnership broadens. #OTC